Goldman Sachs’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Goldman Sachs’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,200	Closed	-$12K	–	5913
2018 Q3	$12K	Sell	7,200 -35,000	-83%	-$62.6K	﹤0.01%	5463
2018 Q2	$73K	Sell	42,200 -35,000	-45%	-$60.5K	﹤0.01%	5278
2018 Q1	$141K	Buy	77,200 +20,000	+35%	+$42.2K	﹤0.01%	5158
2017 Q4	$128K	Hold	57,200	–	–	﹤0.01%	5655
2017 Q3	$166K	Hold	57,200	–	–	﹤0.01%	5862
2017 Q2	$255K	Hold	57,200	–	–	﹤0.01%	5635
2017 Q1	$267K	Hold	57,200	–	–	﹤0.01%	5542
2016 Q4	$348K	Buy	+57,200	New	+$299K	﹤0.01%	5366
2015 Q3	–	Sell	-177,800	Closed	-$1.48M	–	7605
2015 Q2	$1.48M	Buy	+177,800	New	+$862K	﹤0.01%	4155

Other funds holding SGYP

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Goldman Sachs's SGYP Position: Q1 2019 in Review

Goldman Sachs sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 722,369 shares — an estimated $82K sold.

Goldman Sachs first reported a position in SGYP in Q2 2013 and held it in 23 quarters. The position peaked at $9.82M in Q2 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

Goldman Sachs reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
Goldman Sachs sold 722,369 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $82K.
Goldman Sachs first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 23 quarters.
Goldman Sachs's Synergy Pharmaceuticals, Inc Common Stock position peaked at $9.82M in Q2 2017.
12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Goldman Sachs's 13F filing for Q1 2019, filed 15 May 2019.